BNGO - Bionano Genomics: Better Detection Cost Metrics And Saphyr-As-A-Service
- Bionano develops and markets the Saphyr system, used for Optical Genome Mapping (OGM).
- Its OGM technology is proving to be better than the competition in detecting variants, a hot topic given COVID's ability to mutate rapidly.
- Additionally, its technology has been recommended in detection of leukemia and cancer as a lower-cost alternative, after being compared to other standard-of-care methods.
- Impacted by COVID, the company is not operationally profitable currently, requiring injection of cash through sales of equity.
- In view of instrument and samples sales potential, as well as recurrent Saphyr-as-a-Service revenues, the company is a buy.
For further details see:
Bionano Genomics: Better Detection, Cost Metrics And Saphyr-As-A-Service